x

Join Advarra

Learn more about our company team, careers, and values. Join Advarra’s Talented team to take on engaging work in a dynamic environment.

See Jobs

Oncology Research Services

Conduct safer, smarter, faster oncology research with solutions and services that enable collaboration and visibility, ensure compliance, and streamline operations for your cancer clinical trials.​

Advarra’s Contributions to Oncology Research

65%

of industry-initiated oncology trials in the US rely on Advarra solutions

100%

of NCI designated cancer centers conducting clinical trials are supported by Advarra’s IRB

30,000+

investigators rely on Advarra for research participants protections and research performance optimization

By the Numbers

86%

of NCI designated cancer centers collaborate through the Onsemble community

73%

of NCI designated cancer centers manage their trials with OnCore CTMS

600+

research sites conduct gene therapy research with Advarra’s IBC

6.5

business day average IBC review timeline for NCI designated cancer centers

14,752

protocol calendars developed for oncology trials

100+

oncology coverage analyses performed for oncology trials in 2021

100%

increase in startup funding with budget negotiation service

20% More Enrollment, 50% Less Screen Failure, 21% Fewer Protocol Deviations

Learn how a top-20 pharmaceutical company leveraged the Longboat platform to facilitate optimal execution and increase engagement for a uniquely challenging global Phase III breast cancer study.

Sponsors and CROs

Ensure efficient, compliant study conduct for every oncology trial with Advarra’s expert review services, experienced global consultants, and integrated study management, site training, and participant engagement platform.

IRB Review

  • Experienced in overseeing oncology research and led by experts in the field, Advarra’s IRB understands the latest developments to ensure appropriate protections regardless of unique design or complexity.
  • With a roster reflecting the robust expertise oncology research institutions expect, sites are more likely to defer oversight to Advarra as the central IRB. Expertise includes pediatric cancers, rare disease, internal medicine, hematology, women’s cancer, early phase/Phase I oncology, lymphoma, GI/colon cancer, and more.
  • The IRB offers preliminary review feedback for draft protocols to help speed formal review.

IBC Review

  • Speed study startup with the largest network of gene therapy-ready sites in the world: over 500 sites registered and prepared to conduct research involving genetic engineering.
  • Our biosafety experts are knowledgeable in all prevalent types of genetic engineering and gene transfer technology employed oncology research (e.g., CAR T, cancer vaccines, oncolytics, etc.), including numerous individuals who have worked at NCI-designated cancer centers.
  • Coordinated IRB/IBC reviews simplify and accelerate the review process.
  • Ensure sites are prepared to conduct gene therapy research with biosafety site inspections, NIH registration, and other support.

Technology

  • Supported by an intuitive, study-specific interface to ensure compliant and streamlined decentralized activities, the Longboat Platform helps identify sites with realistic patient populations to support complex studies.
  • Enhance protocol compliance by decreasing deviations and queries via study specific trainings for site staff on key aspects of the study and procedures.
  • Manage and oversee site performance globally and within specific regions that may require intervention.
  • Clear patient criteria checklists decrease screen failures.
  • Increase enrollment and retention via engaging materials and visit guides for both sites and participants.

Consulting

  • Understand the most effective pathway for bringing your therapy to market.
  • Navigate the changing global regulatory environment with guidance from veteran industry professionals.
  • Design and implement the infrastructure required for ongoing success.
  • Ensure compliance and consistency with in-person and virtual audit support worldwide.

Sites, Institutions, and Research Networks

Manage reporting requirements, ensure robust research oversight, share best practices, and increase financial viability to focus on what matters with Advarra’s industry-leading technology solutions, expert review services, resource-extending professional services, and a supportive site community.

IRB Review

  • Experienced in overseeing oncology research and led by experts in the field, Advarra’s IRB understands the latest developments to ensure appropriate protections regardless of unique design or complexity. 
  • With a roster reflecting the robust expertise oncology research institutions expect, sites can feel confident deferring IRB oversight to meet sIRB requirements. Expertise includes pediatric cancers, rare disease, internal medicine, hematology, women’s cancer, early phase/Phase I oncology, lymphoma, GI/colon cancer, and more. 
  • The IRB offers preliminary review feedback for draft protocols to help speed formal review. 
  • Advarra is the central IRB for dozens of therapeutically specialized site networks, including multiple oncology groups.

IBC Review

  • Demonstrate your site is prepared to conduct gene therapy research by joining the largest network of gene therapy-ready sites in the world.
  • Our biosafety experts are knowledgeable in all prevalent types of genetic engineering and gene transfer technology employed oncology research (e.g., CAR T, cancer vaccines, oncolytics, etc.), including numerous individuals who have worked at NCI-designated cancer centers.  
  • Coordinated IRB/IBC reviews simplify and accelerate the review process.
  • Biosafety site inspections, NIH registration, SOP development services, and other support ensure your site can safely conduct research involving genetic engineering. 

Technology

  • Built for oncology research and recognized as the field’s preeminent technology platform, Advarra Technology Solutions enable efficient management of complex trials.
  • Facilitate strategic decisions with reports on catchment area requirements, current accrual status, as well as reports on performance of oncology departments. 
  • Ensure complex CCSG reporting requirements are met, and articulate return on research investment with easy-to-use systems. 
  • The Onsemble Community, an unprecedented gathering of oncology research leaders and teams, creates a space for collaborative discussion, problem solving, and standardization that improves oncology research on a national scale. 

Professional Services

  • Alleviate administrative burden, increase research productivity, and maximize your resources with Advarra’s professional services.  
  • Simplify processes and ensure accurate adherence to protocols through efficient CTMS calendar building. 
  • Save time and confirm compliance with Medicare coverage analysis services. 
  • Budget negotiation helps researchers derive adequate funding for trial completion.

Read our Related Resources

 
Blog

Phase I Oncology Clinical Trials

April 26, 2021

In a recent blog, we described the complexity and uniqueness of Phase I clinical trials, outlining the fact that some...

This blog discusses what makes Phase I oncology trials complex and what IRBs need to know as they review a Phase I trial.

Read Now
4 min. read
Read more
 
Podcast

Cheryl Byers and Dr. John H. Stewart Discuss Diversity, Equity and Inclusion in Cancer Research

April 13, 2021

Listen & Subscribe with your preferred player Listen on Spotify Listen on Google Podcasts Listen on Apple PodcastsListen on StitcherRSS...

Diversity, equity, and inclusion (DEI) in cancer research are critical to clinical research. In this episode, Advarra’s Cheryl Byers and Dr. John H. Stewart have a discussion on what is DEI, the current climate of DEI in cancer research, and considerations to improve DEI in clinical trial enrollment and retention.

Listen Now
Read more
 
Blog

Q&A – How Medicare’s New Imaging Program Affects Clinical Trials in Oncology

December 7, 2020

In a recent webinar, Jake Meyer, Business Operations Manager at Advarra, presented How Medicare’s New Imaging Program Affects Clinical Trials...

Jake Meyer answers the most popular questions from his latest webinar: How Medicare’s New Imaging Program Affects Clinical Trials in Oncology.

Read Now
7 min. read
Read more

Visit the Resource Library

Ready to Make Your Oncology Research Safer, Smarter, Faster?  

Contact Us